<DOC>
	<DOCNO>NCT02585895</DOCNO>
	<brief_summary>To evaluate efficacy subcutaneous ( SC ) evolocumab , compare regularly schedule low density lipoprotein cholesterol ( LDL-C ) apheresis , reduce need future apheresis</brief_summary>
	<brief_title>Trial Assessing Evolocumab ( AMG145 ) Compared LDL-C Apheresis Subjects Receiving LDL-C Apheresis Prior Study Enrollment</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<criteria>Male female , ≥ 18 year age Subject receive regular apheresis LDLC lower least 3 month immediately prior lipid screen treatment goal LDLC &lt; 100 mg/dL ( 2.6 mmol/L ) , receive LDLC apheresis last ≥ 4 week prior lipid screen regular QW Q2W schedule change apheresis type Subject receive lipidlowering pharmacological background therapy include highintensity statin dose ( moderateintensity statin dose attestation high dose appropriate subject ) unless subject history statin intolerance Lipidlowering therapy status ( ie , therapy lowering lipid , include apheresis type frequency ) must unchanged ≥ 4 week prior LDLC screen Preapheresis LDLC ≥ 100 mg/dL ( ≥ 2.6 mmol/L ) ≤ 190 mg/dL ( ≤ 4.9 mmol/L ) screen Fasting triglyceride ≤ 400 mg/dL ( 4.5 mmol/L ) screening . Exclusion criterion : Known homozygous familial hypercholesterolemia Missing apheresis session medically contraindicate inappropriate Stopping apheresis would inappropriate opinion investigator even LDLC control &lt; 100 mg/dL therapy Myocardial infarction , unstable angina , percutaneous coronary intervention ( PCI ) , coronary artery bypass graft ( CABG ) stroke within 3 month prior randomization . Uncontrolled hypertension</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>LDL-C Apheresis</keyword>
	<keyword>Hypercholesterolemia</keyword>
	<keyword>Elevated Cholesterol</keyword>
	<keyword>High Cholesterol</keyword>
	<keyword>PCSK9 mutation</keyword>
	<keyword>Severe Familial Hypercholesterolemia</keyword>
	<keyword>evolocumab</keyword>
	<keyword>Repatha</keyword>
</DOC>